Introduction N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoid that inhibits growth and induces apoptosis in many hematological malignancies and solid tumor-derived cell lines, including those that are resistant to natural retinoids. 1 HPR is an effective chemopreventive agent for prostate, cervix, breast, bladder, skin and lung cancers and has shown promise for the treatment of oral pre-malignant lesions and neuroblastomas.
Adult T-cell leukemia-lymphoma (ATL) is an aggressive peripheral T-cell malignancy caused by human T-cell lymphotropic virus type I (HTLV-I). 2 ATL is resistant to chemotherapy and carries a very poor prognosis. The viral transactivator protein Tax plays a critical role in HTLV-I-induced transformation and apoptosis resistance. [3] [4] High response rates in ATL were achieved with the combination of zidovudine and interferon-a. 5 However, most patients eventually relapse, which underlines the need for new therapeutic approaches.
Recently, we have shown that clinically achievable concentrations of HPR cause a dramatic inhibition of cell proliferation, G 0 /G 1 arrest and massive apoptosis in all tested ATL-derived and HTLV-I-negative malignant T cell lines, whereas no effect is observed on normal lymphocytes. 6 Interestingly, HTLV-I-negative cell lines are significantly more sensitive to HPR compared to HTLV-I-positive and Tax-transfected cells.
As HPR is effective in the chemoprevention and treatment of several cancers, elucidating its mode of action is of great interest. The mechanisms of HPR-induced cell death are complex and involve signaling pathways including reactive oxygen species (ROS), ceramide elevation, caspase activation and alterations in mitochondrial membrane potential. [7] [8] [9] All these molecular players are essential for HPR-induced apoptosis as their specific inhibitors abrogate the cell death pathway triggered by this synthetic retinoid. We have shown that in HTLV-I-negative malignant T cells, HPR-induced apoptosis is associated with ceramide accumulation, dissipation of mitochondrial membrane potential and activation of caspases 8, 9 and 3, and could be partially reverted by caspase inhibitors. We also showed that Tax protects infected cells from ceramide accumulation and caspase-mediated apoptosis. 6, 10 In several cell types, activation of the mitochondrial pathway is essential for HPR-induced apoptosis. 9, [11] [12] Cytochrome c release from mitochondria, which triggers caspase activation, has been also implicated in HPR-induced apoptosis. 9, 11, 13 ROS are largely produced in mitochondria, and represent important mediators of cell cycle progression and apoptotic cell death.
In this report, we investigated the role of ROS in HPR-induced apoptosis in HTLV-I-negative and -positive malignant T cells. Our results demonstrate that HPR acts as an oxidant, inducing ROS-mediated cell death, particularly in HTLV-I-negative malignant T cells. We also show that HPR-induced ceramide accumulation, cell cycle arrest, caspase activation and apoptosis are secondary to ROS generation. Finally, we report that Tax expression abrogates HPR-induced ROS accumulation in HTLV-I-infected cells, which explains their lower sensitivity to HPR.
Materials and methods

Cells and drugs
The HTLV-I-transformed T cell lines HuT-102 and MT-2 and the HTLV-I-negative T cell lines CEM, Jurkat and Molt-4 were grown, as described previously. 14 and stored in amber tubes at À801C. Before HPR addition, cells were cultured for 24 h at 1 Â 10 5 cells/ml. In all assays, HPR was used at 5 mM and experiments were performed under yellow light (l4500 nm) to prevent photoisomerization. The final concentration of DMSO never exceeded 0.1% and this concentration showed no effect on the proliferation of all tested cell lines (data not shown). The anti-oxidants vitamin C (ascorbic acid sodium salt; Sigma Chemical Co) and dithiothreitol (DTT) (Fisher Biotech, Wembley, Western Australia, Australia), the oxidant buthionine sulphoximine (BSO) (Sigma Chemical Co) and the caspase inhibitor zVAD (Bachem Bioscience, King of Prussia, PA, USA) were added 2 h before HPR at a final concentration of 100, 50 and 50 mM, respectively.
Growth assay and cell cycle analysis
Cell growth was assessed by the use of the CellTiter 96 nonradioactive cell proliferation assay kit (Promega Corp., Madison, WI, USA), according to the manufacturer's instructions, as described previously 16 and the Trypan blue dye exclusion protocols. Cell cycle analysis was performed as described 6 using propidium iodide (50 mg/ml) (Sigma) staining and a FACS scan flow cytometer (Becton Dickinson, San Jose, CA, USA).
Measurement of ROS
Generation of intracellular ROS was measured using 2 0 -7 0 -dichlorofluorescin diacetate (H 2 DCFDA) upon oxidation to the fluorescent derivative 2 0 -7 0 -dichlorofluorescin by reactions with ROS. We used the ROS kit: CM-H 2 DCFDA (Molecular Probes, Eugene, OR, USA) according to the manufacturer's instructions. Following indicated treatments, cells were span down and resuspended in 500 ml RPMI containing 2% fetal bovine serum and 10 mM H 2 DCFDA for 20 min at 371C. Subsequently, cells were washed twice with phosphate-buffered saline and then analyzed with a FACS scan flow cytometer (Becton Dickinson, San Jose, CA, USA) with excitation set at 488 nm and emission at 530 nm.
Measurement of cytochrome c release and mitochondrial membrane potential
Cytochrome c release was measured using the Cytochrome c ELISA Kit (EMD Biosciences, Darmstadt, Germany). Subcellular fractionation was performed before solubilization as described previously. 17 Subsequently, apoptotic cytochrome c was measured in the cytosolic fraction according to the manufacturer's instructions. Cytochrome c levels were assayed by OD measurement at 450 nm using an ELISA microplate reader. Quantitation of mitochondrial membrane potential was determined by rhodamine R123 retention as described. 6 
Caspase activation assays
Caspase activity was measured using the ApoTarget Caspase Colorimetric Assay Sampler Kit (Biosource International, CA, USA), according to the manufacturer's instructions, as described. 6 
Ceramide measurement
Ceramide was measured with a modified diacylglycerol kinase assay using external ceramide standards as described. 10 
Immunoblot analysis
Total cellular proteins were boiled and loaded (30 mg/lane) onto a 10% SDS-polyacrylamide gel, subjected to electrophoresis and transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA). Western blot analysis was performed as described. 6 The following primary antibodies were used: Rabbit polyclonal antibodies against p21, caspase 8, caspase 9 and PARP (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); mouse monoclonal anti-Tax (168-A51) (NIH AIDS Research and Reagent Program) and anti-caspase 3 antibodies (Pharmingen, CA, USA). To ensure equal protein loading, blots were striped and reprobed with glyceraldehyde-3-phosphate dehydrogenase (Biogenesis, Stinford Fload, UK). Detection was performed by chemiluminescence (Amersham, Buchinghamshire, UK).
Statistical analysis
The two-sample Student's t-test was performed to validate the significance of the observed results.
Results
HPR-induced growth inhibition of malignant T cells is associated with ROS accumulation
We have previously demonstrated that, at clinically achievable concentrations, HPR is a potent and selective inducer of G 0 /G 1 cell cycle arrest and apoptosis in HTLV-I-positive and -negative malignant T cells, whereas no effect is observed on resting or activated normal lymphocytes. 6 However, HTLV-I-negative cell lines are significantly more sensitive to HPR compared with HTLV-I-positive and Tax-transfected cells. The mechanisms of HPR-induced cell death are complex and involve multiple signaling pathways; some of them are associated with accumulation of ROS. 18 To investigate the involvement of ROS in HPR effects, we measured ROS levels at different time points following treatment of HTLV-I-negative (CEM, Jurkat, and Molt-4) and HTLV-Ipositive (HuT-102 and MT-2) malignant T cell lines. Cells were continuously treated with 5 mM HPR for up to 48 h. As previously reported, 6 HPR treatment for 24 h significantly reduced the growth of CEM and Jurkat cells by 66 and 77%, respectively 
ROS accumulation mediates HPR-induced growth inhibition
To explore the direct role of the observed ROS accumulation in HPR-induced growth inhibition and apoptosis, malignant T cells were pre-treated for 2 h with the anti-oxidant agents, vitamin C and DTT, and then treated with HPR. Pre-treatment with vitamin C had no significant effect on HPR-induced mitochondrial membrane dissipation in HTLV-Inegative (CEM and Jurkat) and -positive (HuT-102 and MT-2) malignant T cells (Figure 3a and data not shown). However, vitamin C pre-treatment completely abolished HPR-induced cytochrome c release in all tested cells at 2 and 6 h and significantly reduced cytoplasmic cytochrome c levels at 12 h. Altogether, these results indicate that HPR-induced ROS accumulation mediates cytochrome c release independently from mitochondrial membrane potential dissipation. They also demonstrate that ROS generation rather than mitochondrial membrane dissipation is the key player in HPR-induced growth inhibition of malignant T lymphocytes.
ROS generation mediates HPR-induced caspase activation
We have previously demonstrated that HPR treatment induced caspase-mediated apoptosis in HTLV-I-negative malignant T cells. 6 This caspase activation may be secondary to cytochrome c release. 19 To explore the role of ROS accumulation in caspase activation, activities of caspases 3, 8 and 9 were measured in HPR-treated CEM and HuT-102 cells. In accordance to our previous findings, treatment with 5 mM HPR for 24 h significantly induced activation of caspases 3, 8 and 9 in CEM cells and to a lesser extent in HuT-102 cells (Darwiche et al. 6 and Figure 4a ), reflecting the lower sensitivity of the latter cells to HPR. Pretreatment with vitamin C abolished HPR-induced caspase activation in HTLV-I-negative and-positive malignant T cells. Moreover, HPR treatment induced a massive cleavage of procaspases 3, 8 and 9 and of the caspase-substrate PARP in CEM cells, whereas minimal cleavage was observed in HuT-102 cells, confirming the caspase activation results (Figure 4b ). Pretreatment with vitamin C abolished HPR-induced pro-caspase and PARP cleavage. These results demonstrate that HPRinduced caspase activation is mediated by ROS accumulation, particularly in HTLV-I-negative malignant T cells. Finally, we have analyzed the effect of the general caspase inhibitor zVAD on HPR-induced ROS production in CEM, Jurkat and HuT-102 cells. We found that addition of zVAD did not affect HPRinduced ROS accumulation whereas it had a partial protective effect on cell death (Figure 4c) , as previously reported. 6 This confirms that HPR-induced ROS accumulation is upstream of caspase activation. 
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ROS generation mediates HPR-induced ceramide accumulation and apoptosis
We have shown that HPR-mediated cell cycle arrest and apoptosis are associated with ceramide accumulation in HTLV-I-negative cells 6, 10 and downregulation of p21 protein levels in HTLV-I-positive cells. 6 To investigate the role of ROS generation in these HPR-related effects, levels of ceramide and p21 proteins were measured in HPR-treated cells after pre-treatment with vitamin C. Treatment of CEM cells with 5 mM HPR for 24 h resulted in approximately fourfold increase in intracellular ceramide levels as compared to untreated controls (Figure 5a ). This HPR-induced increase in cellular ceramide was not observed in BSO-treated CEM cells, demonstrating that this effect is HPR specific. Interestingly, pre-treatment with vitamin C decreased cellular ceramide levels in HPR-treated CEM cells down by twofold compared to untreated controls. As reported, no significant change in cellular ceramide levels was detected in HuT-102 cells. 10 Moreover, in these HTLV-I-positive cells, pre-treatment with vitamin C had no effect on HPR-induced downregulation of p21 protein levels (Figure 5b ). These results demonstrate that HPR-induced ROS generation mediates ceramide accumulation in HTLV-I-negative malignant lymphocytes, whereas HPR-induced p21 downregulation in HTLV-I-infected cells is ROS-independent.
We then analyzed changes in cell cycle distribution in HPRtreated cells following pre-treatment with vitamin C. HPR induced a significant increase in the apoptotic pre-G 1 cells, more so in the HTLV-I-negative CEM and Jurkat cells (Figure 5c and data not shown). Indeed, treatment of CEM and Jurkat cells with 5 mM HPR for 24 h increased the apoptotic pre-G 1 region from 3% to approximately 35% as compared to only 20% in HuT-102 and MT-2 cells (Figure 5c and data not shown). Pretreatment with vitamin C abolished HPR-induced apoptosis. HPR treatment also induced a moderate G 0 /G 1 cell cycle arrest, particularly in HTLV-I-negative cells, as the number of CEM cells in these phases increased from 68 to 80%. This HPRinduced cell cycle arrest in HTLV-I-negative cells was reduced with vitamin C pre-treatment. Altogether, our results demonstrate that HPR-induced ROS generation mediates cell cycle arrest and caspase-dependent apoptosis in HTLV-I-negative malignant T cells.
Tax expression abrogates HPR-induced ROS accumulation and growth inhibition
That HTLV-I-positive cells are protected against HPR-induced ROS accumulation may explain their lower sensitivity to HPR's effects. The HTLV-I oncoprotein Tax interferes with multiple cellular pathways and protects infected cells from caspase activation and apoptosis. 20 To explore the effect of Tax expression on HPR-induced ROS generation, ROS levels were measured at different time points following treatment of Taxtransfected HeLa and Jurkat cells. ROS levels were lower in HPR-treated Tax-transfected HeLa and Jurkat cells as compared to mock-transfected controls (PSG-5 cells) (Figure 6a) . Indeed, treatment of mock-transfected HeLa cells with 5 mM HPR resulted in a progressive increase in ROS levels. This increase was visible as early as 2 h and reached almost 40% of control cells at 12 h post-HPR treatment. Tax transfection significantly attenuated HPR-induced ROS generation, which barely increased by 10% at 12 h post-treatment. Similar effects were observed in Jurkat cells, although Tax effects were less dramatic on inhibition of HPR-induced ROS generation, likely because of lower transfection efficiency (Figure 6a and data not shown) . Furthermore, Tax expression significantly attenuated HPRinduced growth inhibition of both HeLa and Jurkat cells (Po0.01, t-test) (Figure 6b ). These results demonstrate that Tax expression abrogates HPR-induced ROS accumulation in HTLV-I-infected cells, which explains their lower sensitivity to HPR. To investigate the possibility that Tax-induced nuclear factor-kB (NF-kB) activation mediates its effects on HPR-induced ROS accumulation, we used the NF-kB-defective, CREB-active, Tax mutant M22 and the NF-kB-active, CREB-defective, Tax mutant M47. 15 Unlike wild-type Tax, these two mutants increased, rather than decreased, HPR-induced ROS accumulation in both HeLa-and Jurkat-transfected cells (Figure 6a ). These results demonstrate that Tax-mediated abrogation of HPR-induced ROS production requires both NF-kB and CREB activation.
Discussion
In this report, we identified HPR-induced ROS generation as the key mediator of HPR-induced cell cycle arrest and apoptosis in malignant T cells. Indeed, HPR treatment of HTLV-I-negative malignant T cells was associated with a rapid and progressive increase in ROS levels. Importantly, pre-treatment with antioxidants, which inhibited ROS generation, prevented HPRinduced ceramide accumulation, cell cycle arrest, cytochrome c release, caspase-activation and apoptosis. Furthermore, the pro-oxidant agent BSO synergized with HPR in inducing ROS accumulation and growth inhibition in HTLV-I-negative and -positive malignant T cells. Similarly, a previous study showed 
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that BSO increased cytotoxicity of aluminum-mediated cell death of PC12 rat pheochromocytoma cells, whereas BSO alone had moderate effects on cell viability. 21 In that model, BSO decreased the intracellular levels of the anti-oxidant glutathione through inhibition of GSH synthase. A similar mechanism could be envisioned in our model.
Previous reports have implicated ROS generation in HPRmediated apoptosis, particularly in myeloid leukemia cells, neuroblastoma, epidermal squamous cell carcinoma (SCC), head and neck SCC, prostate, lung and cervical carcinoma cells and recently in B-cell lymphomas. 8, [11] [12] [22] [23] [24] [25] However, in most of these studies, ROS accumulation was considered secondary to ceramide accumulation or independent from ceramide accumulation and caspase-dependent apoptosis. 26 Our results clearly indicate that ROS generation represents the primary event in HPR's effects, upstream of both ceramide synthesis and caspase activation.
The mechanisms of HPR-induced ROS generation remain to be elucidated. Several studies implicated the mitochondrial permeability transition as being crucial for HPR-induced apoptosis 9, 11 , occurring at a quinone-binding site in complex I and center o of complex III 23 and involving the proapoptotic Bcl-2 family members Bax and/or Bak 12 or Gadd153. 27 That HPR treatment induced a delayed dissipation of mitochondrial membrane potential, in both untreated and vitamin C pre-treated cells, indicates that HPR-induced ROS generation is independent from mitochondrial membrane dissipation in malignant T lymphocytes. Other reports have implicated protein kinase C and mitogen-activated protein (MAP) kinases and 12-lipoxygenase in HPR-induced ROS generation and apoptosis induction. 28 It is of interest to determine whether similar pathways exist in HPR-treated malignant T cells and their possible regulation by Tax. On the other hand, we have previously shown that HPR induces growth inhibition, cell cycle arrest and apoptosis in all tested malignant T-cells, including all-trans-retinoic acid (ATRA)-resistant cells. 6 The larger spectrum of HPR compared to ATRA may be explained by the fact that ATRA effects are mediated solely by the retinoic acid receptors (RARs), while HPR may function through both RAR-dependent and -independent mechanisms. 27 Therefore, HPR-induced ROS generation is likely RARindependent. 11, 22 In contrast, a completely different mechanism of action of HPR was observed in HTLV-I-positive cells. In these cells, HPR treatment induced caspase-independent apoptosis and had no significant effect on ceramide levels. Here, we show that HTLV-I-positive cells are protected against HPR-induced ROS generation and that Tax expression abrogates HPR-induced ROS accumulation. That HTLV-I-negative cells are more sensitive than their HTLV-I-positive or Tax-transfected counterparts to HPR suggests that Tax or Tax-induced constitutive activation of the NF-kB pathway 29 may protect HTLV-I-transformed cells from ROS generation and subsequent ceramide accumulation and caspase-dependent apoptosis.
On the other hand, in HTLV-I-positive cells only, HPR treatment rapidly induced an ROS-independent proteasomalmediated degradation of p21 (Darwiche et al. 6 and Figure 5b ). Expression of p21 is upregulated at both transcript and protein levels in HTLV-I-infected cells, as Tax transactivates the p21 promoter. 30 Furthermore, p21 was recently shown to prevent apoptosis and to stimulate the growth of HTLV-I-positive cells. 31 Hence, the early HPR-induced downregulation of p21 in HTLV-I-positive cells may contribute to HPR-induced cell cycle arrest owing to the removal of this anti-apoptotic and mitogenic factor in Tax-expressing cells.
We propose a model ( Figure 7 ) whereby rapid and progressive ROS generation represents an early and central event in HPRtreated malignant T cells. This increase in intracellular ROS levels results in ceramide accumulation, cell cycle arrest, cytochrome c release, caspase-activation and caspase-dependent apoptosis. Pre-treatment with anti-oxidants or Tax expression in HTLV-I-infected cells, both of which inhibit ROS generation, prevent the secondary cellular events and therefore, protect cells from HPR-induced growth inhibition. In conclusion, defining the mechanism of free radical induction by HPR may support the potential therapeutic role for HPR in ATL and HTLV-I-negative peripheral T cell lymphomas and the search of other compounds that synergize with conventional chemotherapeutic drugs. 
